Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4268989 (MORF-057) plus mirikizumab versus mirikizumab in moderately to severely active ulcerative colitis
jRCT2031250463Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing LY4268989 + mirikizumab with mirikizumab + LY4268989 placebo (2 arms). Primary endpoint: Percentage of participants who achieve clinical remission with modified Mayo score. Started Mar 2026; status: recruiting.
02
Drugs
LY4268989mirikizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2031250463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250463.